Home / Contract Awards / Emergent BioSolutions Gets $1.25 Billion Contract to Supply Anthrax Vaccine

Emergent BioSolutions Gets $1.25 Billion Contract to Supply Anthrax Vaccine

The U.S. government has selected Emergent BioSolutions Inc. (NYSE: EBS) to supply millions of doses of its anthrax vaccine over five years on a contract worth up to $1.25 billion.

Contract work will begin this year and calls for Emergent to deliver a total of 44.75 million doses of BioThrax. In the first contract year, 8.5 million doses are scheduled to be delivered. The vaccine will be delivered through September 2016.

The U.S. Food and Drug Administration has licensed BioThrax to protect against anthrax infection.

“This five-year award provides for uninterrupted supply of this critical biodefense countermeasure while addressing the government’s mandate to reduce spending across all programs, ” said Emergent CEO Fuad El-Hibri.

Check Also

K2-FIN Alert: US Gets Upgraded FATF Rating Due to Customer Due Diligence Rule Implementation

An alert from K2 Intelligence-Financial Integrity Network says the Financial Action Task Force has upgraded the U.S. from “partially compliant” to “largely compliant” with Recommendation 10 after it implemented the U.S. Treasury’s requirements for customer due diligence.

DoD Releases 5G Spectrum-Sharing Prototype Solicitation; National Spectrum Consortium’s Joseph Dyer Quoted

The Department of Defense has issued a request for prototype proposals seeking spectrum-sharing concepts from members of the National Spectrum Consortium to support 5G development and test activities at military bases in Utah.